Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis, Utilisation of Health Care Resources in Patients With COPD

Philipps University Marburg2,741 enrolled

Overview

The purpose of this study is to determine the prevalence and severity of extrapulmonary disorders and to quantify the impact of extrapulmonary organ manifestations on morbidity and mortality of COPD patients. Furthermore the investigators evaluate the relationship between systemic inflammation and organ involvement.

Chronic diseases and comorbidities have an increasing impact on individual life and health care use, as exemplified in chronic obstructive pulmonary disease (COPD). Currently, independent, comprehensive databases allowing for an integrated view are lacking. The study will for the first time establish a large, comprehensive longitudinal database covering a broad panel of comorbidities an markers of systemic alterations. These data will be of unique value in revealing specific phenotypes of COPD via patterns and risk profiles of comorbidities, enabling a more precise diagnosis and targeting of therapy, and an efficient allocation of resources.

Study Type

OBSERVATIONAL

Enrollment

2,741

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * aged 40 years and older * diagnosis of COPD (GOLD-Criteria) or chronic bronchitis * informed consent * available for repeated study visits pver 18 months Exclusion Criteria: * having undergone big lung surgery (e.g. lung reduction, lung transplant) * Moderate or severe exacerbation within the last 4 weeks * having a lung tumor * Unable to walk or to understand the intention of the project

Locations (22)

Ev. Lungenklinik (ELK), Krankenhausbetriebs gGmbH, Pneumologische Klinik

Berlin, Germany

Outcomes

Primary Outcomes

Change from baseline in BODE-Score at 18 months

The BODE-Score comprises BMI, airway obstruction, dyspnea and exercise capacity and is a good predictor for death in COPD patients. Progression is defined as a change in BODE-score by \>=1 point over the observation period.

Time frame: at initial visite, after 18, 36, 54, 72, 90 and 108 months

Secondary Outcomes

COPD related mortality

The rate of mortality was elevated after 6, 18, 36, 54, 72, 90 and 108 months

Time frame: after 18 months

COPD related hospitalization

The rate of hospitalizations was elevated in every visit.

Time frame: after 18, 36, 54, 72, 90 and 108 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.